

Estimate change	
TP change	
Rating change	

Bloomberg	BIOS IN
Equity Shares (m)	1201
M.Cap.(INRb)/(USDb)	435.3 / 5
52-Week Range (INR)	405 / 244
1, 6, 12 Rel. Per (%)	0/6/27
12M Avg Val (INR M)	2105

Financials & Valuations (INR b)

Y/E March	FY25E	FY26E	FY27E
Sales	148.1	167.2	195.3
EBITDA	29.4	35.5	44.0
Adjusted PAT	-0.2	4.6	10.7
EBIT Margin (%)	8.6	10.7	13.2
Cons. Adj EPS (INR)	-0.1	3.9	9.0
EPS Gro. (%)	NA	NA	131.2
BV/Sh. (INR)	169.2	172.0	178.3
Ratios			
Net D-E	0.8	0.7	0.7
RoE (%)	-0.1	2.3	5.1
RoCE (%)	2.2	3.2	4.7
Payout (%)	29.3	29.3	29.3
Valuations			
P/E (x)	NA	92.2	39.9
EV/EBITDA (x)	18.6	15.3	12.5
Div. Yield (%)	0.4	0.3	0.6
FCF Yield (%)	3.4	5.4	7.8
EV/Sales (x)	3.7	3.3	2.8

Shareholding pattern (%)

As On	Dec-24	Sep-24	Dec-23
Promoter	60.6	60.6	60.6
DII	15.4	14.4	14.5
FII	5.9	6.2	6.9
Others	18.1	18.8	18.0

FII Includes depository receipts

CMP: INR363
TP: INR420 (+16%)
BUY
Execution in Biologics/Syngene drives operational performance
Compliance provides better visibility for niche approval/launches

- Biocon (BIOS) delivered a better-than-expected operational performance in 3QFY25. However, earnings came in below our estimate due to a higher tax outgo. BIOS has been witnessing improved traction in the biologics segment on the back of steady market share gains and its increasing reach in new geographies. After three quarters of YoY revenue declines, Syngene delivered YoY sales growth in 3QFY25, led by better traction in research, CMO and biologics segments.
- While we maintain our sales/EBITDA estimates, we reduce our earnings estimates by 13%/4% for FY26/FY27, factoring in a higher tax rate. We value BIOS on SOTP basis (22x 12M forward EV/EBITDA for 73% stake in Biocon Biologics, 53% stake in Syngene and 14x EV/EBITDA for generics business) to arrive at a TP of INR420.
- With USFDA GMP compliance at Biocon park and Malaysia facility and b-Stellara approval, we expect the company's sales trajectory to strengthen going forward. In fact, the regulatory compliance provides better visibility for Insulin Aspart approval as well, which would be another niche opportunity for BIOS in FY26. We expect Syngene to also deliver better growth in FY25-27 compared to FY23-25 on the back of demand tailwinds and Syngene's capability/capacity. Further, BIOS is implementing efforts in the peptide space within the generics segment, with commercial benefits expected FY26 onward. Maintain BUY.

Operating leverage outweighs higher RM costs

- 3QFY25 revenue grew 6% YoY to INR38.2b (est. INR37.1b). Research services (24% of sales) grew 11% YoY to INR9.4b. Biosimilars (58% of sales) declined 8% YoY to INR2.3b. Generics sales declined 2% YoY to INR6.9b.
- Gross margin (GM) contracted 140bp YoY to 62%.
- EBITDA margin expanded 370bp YoY to 19.7% (est. 19.5%), as lower R&D/other expenses (-390bp/-490bp YoY as % of sales) were offset by higher employee costs (+370bp YoY as % of sales).
- EBITDA grew 30.3% YoY to INR7.5b (est. INR7.2b).
- After adjusting a one-off expense of INR163m and a one-time tax outgo of INR95m for SYNG, BIOS reported PAT of INR339m vs. a loss of INR1.7b in 3QFY24 (est. PAT: INR715m).
- During 9MFY25, revenue/EBITDA grew 3%/1% YoY to INR108b/INR20.6b. BIOS reported an adj. loss of INR900m in 9MFY25 vs. a profit of INR742m last year.

Highlights from the management commentary

- BIOS maintains growth outlook for 2HFY25 and FY26 at the group level.
- BIOS expects to sustain EBITDA margin at 22-23% over the next 18-24 months at BBL level.

Tushar Manudhane - Research Analyst (Tushar.Manudhane@MotilalOswal.com)

Research Analyst - Akash Manish Dohbada (Akash.Dohbada@MotilalOswal.com | **Viraj Shah** (Viraj.Shah@MotilalOswal.com))

Investors are advised to refer through important disclosures made at the last page of the Research Report.

Y/E March									(INRb)		
	FY24				FY25E				FY24	FY25E	FY25E
	1Q	2Q	3Q	4Q	1Q	2Q	3Q	4Q		3QE	vs Est
Net Sales	34.2	34.6	36.0	39.2	34.3	35.9	38.2	39.6	144.1	148.1	37.2 2.8%
YoY Change (%)	57.9	49.2	22.5	7.4	0.3	3.7	6.0	1.2	30.0	2.8	3.1
Total Expenditure	27.1	27.2	30.3	30.0	28.1	29.0	30.4	31.1	114.6	118.6	29.9
EBITDA	7.1	7.4	5.8	9.2	6.2	6.9	7.9	8.5	29.5	29.4	7.2 8.4%
YoY Change (%)	53.5	57.4	-16.3	5.1	-12.9	-7.4	36.2	-7.2	18.1	-0.1	25.7
Margins (%)	20.8	21.4	16.0	23.4	18.1	19.1	20.6	21.5	20.5	19.9	19.5
Depreciation	3.6	3.9	4.2	4.1	4.1	4.2	4.3	4.2	15.7	16.7	4.2
EBIT	3.6	3.5	1.6	5.1	2.2	2.7	3.6	4.3	13.8	12.7	3.1
Interest	2.3	2.5	2.7	2.3	2.4	2.3	2.2	2.1	9.8	8.9	2.1
Other Income	0.9	1.6	1.1	0.5	0.8	0.3	0.4	0.5	4.1	1.9	0.6
Extraordinary Income	0.0	-0.2	8.3	-0.1	10.9	0.3	-0.2	0.0	7.9	11.0	0.0
Share of Profit/Loss from Associates	-0.3	-0.2	-0.2	0.0	0.0	0.0	0.0	0.0	-0.8	0.0	0.0
PBT	1.8	2.1	8.1	3.2	11.5	1.0	1.6	2.7	15.2	16.7	1.5 3.0%
Tax	0.4	0.4	0.6	1.0	2.8	0.7	0.8	1.5	2.3	5.8	0.3
Rate (%)	19.1	19.6	6.8	30.1	24.8	71.4	47.9	57.5	15.0	35.0	20.0
Minority Interest	0.5	0.5	0.9	0.9	2.0	0.4	0.6	0.4	2.8	3.4	0.5
PAT	1.0	1.3	6.6	1.4	6.6	-0.1	0.3	0.7	10.2	7.4	0.7 -64.4%
Adj PAT	1.0	1.4	-1.7	1.4	-1.6	0.4	0.3	0.7	2.2	-0.2	0.7 -52.5%
YoY Change (%)	-51.1	-16.2	-176.5	-5.0	NA	-74.7	NA	-48.7	-71.1	NA	-141.9
Margins (%)	2.9	3.6	18.3	3.5	19.2	-0.4	0.7	1.8	7.1	5.0	1.9

Key performance Indicators (Consolidated)

Y/E March									FY24	FY25E	FY25E
	1Q	2Q	3Q	4Q	1Q	2Q	3Q	4QE			
											3QE
Cost Break-up											
RM Cost (% of Sales)	38.7	35.4	36.6	36.2	37.2	35.6	38.0	37.8	36.7	37.2	35.9
Staff Cost (% of Sales)	15.2	15.3	15.4	13.6	20.4	20.8	19.1	18.4	14.8	19.6	20.2
R&D Expenses(% of Sales)	9.2	7.6	9.1	6.3	6.6	5.6	5.2	5.4	8.0	5.7	6.3
Other Cost (% of Sales)	16.1	20.2	22.8	20.6	17.7	18.9	17.1	16.9	20.0	17.6	18.1
Gross Margins (%)	61.3	64.6	63.4	63.8	62.8	64.4	62.0	62.2	63.3	62.8	64.1
EBITDA Margins (%)	20.8	21.4	16.0	23.4	18.1	19.1	20.6	21.5	20.5	19.9	19.5
EBIT Margins (%)	10.4	10.2	4.5	13.0	6.3	7.4	9.4	10.9	9.6	8.6	8.3

E: MOFSL Estimates

**Conference call highlights****Segmental margins:**

- EBITDA margin for Biocon Biologics stood at 21.3% (down 1220bp YoY/20bp QoQ).
- EBITDA margin for Syngene was 30.1% (up 290bp YoY/150bp QoQ basis).
- The generics business reported EBITDA margin loss of 2.8%, which improved from -52.4% YoY/-5.9% QoQ.

BBL (58% of total revenue):

- BIOS has guided for R&D expenses at 7-9% (as % of sales) over the next 18-24 months.
- It plans to launch bUstekinumab in US/EU market in Feb'25.
- The company has filed bDenosumab in the US, EU, Japan and other geographies. It expects to launch the product by early or mid-FY26.

- The growth in biosimilars would come from expansion in EU markets and tender wins in EM market.
- BIOS is witnessing volume growth and steady price erosion in the US market.
- It expects to launch five biosimilars in the US market and three globally.
- Geography-wise revenue share for NA:EU:EM is 45:30:25.
- The company is expanding its reach in the Mediterranean and UK-Nordics regions.
- Insulin Aspart remains a potential opportunity given no competition for the product.

Generics (17% of total revenue):

- The company expects mid-teen growth in FY26, driven by niche product launches like GLP-1, tacrolimus and other OSDs.
- In 4QFY25, BIOS plans to launch GLP-1 product in EU and UK markets and expects approval of GLP-1 in the US market in 2HFY26.
- BIOS has filed US DMF for Semaglutide. It has done bio-equivalence study in India and is ready to file in certain geographies. Approvals are expected by CY26 end.
- The OSD facility acquired by BIOS in Cranbury, US, has been qualified by USFDA. The site has three approved statin products, which are vertically integrated, and the company has started commercial supply of the product.
- BIOS has secured a contract from government agencies in the US for national supply of statin products recently.
- During the quarter, BIOS has filed two ANDA in the US market. It has received approval for seven products globally, including one for the US market.
- BIOS will file semaglutide product in Canada, Brazil, Mexico and other markets in 1QFY26. It has already filed DMF in the US market for semglutide.
- Initially BIOS will launch semaglutide from the CMO site; however, it is building semaglutide capacity for the US and EU markets, which will be commercialized in FY26.
- BIOS expects to file semaglutide in Canada in 1HFY26.

Syngene (24% of total revenue):

- SYNG expects revenue growth in FY25 to be in single digits, implying strong YoY growth in 4QFY25. SYNG indicated flat YoY PAT for FY25.
- SYNG has guided for a capex of USD60m for the year.
- ETR stood at 22.2% in 3QFY25 (vs. 19.3% in 3QFY24).
- Capex was USD34m (50% in Research Services and 25% of multi-modal facility (Unit 3) of Stelis Biopharma) for 9MFY25.
- Net cash was INR8.4b as of Dec'24.

Other key highlights:

- As of Dec'24, net debt stood at USD1.3b in BBL and USD100m in generics, whereas Syngene has net cash of USD100m.

Key exhibits

Exhibit 1: Research services witness a jump in PBT margins

	Segmental PBT margin	3QFY22	4QFY22	1QFY23	2QFY23	3QFY23	4QFY23	1QFY24	2QFY24	3QFY24	4QFY24	1QFY25	2QFY25	3QFY25
Generics		11.0	16.1	10.4	8.7	10.0	9.9	9.2	9.8	7.0	7.0	2.6	-1.4	-2.0
Biosimilars		20.5	14.7	7.2	7.8	6.8	7.8	1.2	-0.8	-7.2	3.8	51.1	-0.8	0.0
Novel Biologics		-307.5	-412.2	NA	NA	NA	-200.5	NA	NA	NA	NA	NA	NA	NA
Research Services		20.0	23.6	14.4	16.9	17.8	23.2	15.2	17.4	16.6	22.8	8.8	15.4	19.2
Total		12.4	16.1	9.2	10.6	8.4	10.0	5.4	6.9	12.1	8.4	32.4	2.0	3.6


Source: MOFSL, Company

Exhibit 2: Syngene International – financials

(INR m)	3QFY25	3QFY24	%YoY	2QFY25	%QoQ
Total revenues	9,437	8,535	10.6	7,897	19.5
Material cost	2,374	2,374	-	2,335	1.7
Gross profit	7,063	6,161	14.6	5,562	27.0
Gross margin (%)	74.8	72	265.9	70.4	441
Staff cost	2,495	2,209	12.9	2,299	8.5
% of sales	26.4	26	55.7	29.1	(267)
Other expense	1,732	1,637	5.8	1,565	10.7
% of sales	18.4	19	-82.7	19.8	(146)
EBITDA	2,836	2,315	22.5	1,698	67.0
EBITDA margin (%)	30.1	27	292.8	22	855
Depreciation	1,087	1,081	0.6	1,069	1.7
EBIT	1,749	1,234	41.7	629	178.1
Interest cost	124	108	14.8	117	6.0
Other income (net)	183	293	(37.5)	181	1.1
PBT before EO	1,808	1,419	27.4	693	160.9
EO expense	0	37	-	-320	-
PBT	1,808	1,382	30.8	1,013	78.5
Income tax	497	267	86.1	256	94.1
Effective tax rate (%)	27.5	19.3	-	25.3	-
Adjusted PAT	1311	1,145	14.5	518	153.2


Source: MOFSL, Company

Exhibit 3: Revenue grew 6% YoY in 3QFY25




Source: MOFSL, Company


Exhibit 4: Biosimilars contributed 58% to total revenue




Source: MOFSL, Company

Exhibit 5: EBITDA margin contracted 460bp YoY in 3QFY25


Source: MOFSL, Company

Exhibit 6: The entire R&D spending was expensed out

Source: MOFSL, Company

Exhibit 7: R&D expense as % of sales decreased on QoQ basis

Source: MOFSL, Company

Exhibit 8: Net profit was INR339m in 3QFY25

Source: MOFSL, Company

Gearing for growth across segments

Biologics – Site clearance improves visibility for new launches and approvals

- In 9MFY25, the biologics segment was stable YoY at INR66b, led by traction in its new products and the expansion in new markets, offset by price erosion in key markets.
- BIOS is also witnessing market share gains for key launches like bBevacizumab, bPegfilgrastim, and bHumira in the EU, Japan, Australia, South Africa and New Zealand. Additionally, BIOS is witnessing strong demand for its key products in Mexico, Saudi Arabia, Mediterranean and UK-Nordics clusters.
- The approval of b-Ustekinumab and its subsequent launch in Feb'25 will drive growth and market share gain, as BIOS is in the first phase of the launch.
- With clearance of Biocon park and Malaysia facility from USFDA, b-bevacizumab and b-Aspart remain interesting opportunities for growth over the near to medium term, with limited to no competition in products.
- Having said this, BIOS has filed b-Donsumab in the US market and has won several tender contracts in EM markets, which will be key growth drivers going forward.
- We expect a 15% sales CAGR to INR115b over FY25-27.

Generics – Working on niche launches to drive growth over medium term

- Generics business sales declined 5% YoY to INR20b in 9MFY25, due to demand and pricing challenges in the base portfolio and a planned facility shutdown.
- The generics business is making progress by expanding its portfolio, geographic reach, as well as strengthening its manufacturing base.

- During the quarter, BIOS received approval for the Liraglutide in the EU market and tacrolimus in China.
- BIOS expects to launch semaglutide in FY26 in Canada, Brazil, Mexico and other geographies.
- With the acquisition of Cranbury for statin products, BIOS is well placed to cater to US demand through government tenders.
- Further, BIOS is focusing on peptides and fermentation-based products such as high-potent fermentation and microbial fermentation.
- We expect a 14% revenue CAGR over FY25-27 to INR34.4b.


Research Services – rise in demand/new contracts to drive growth

- In 9MFY25, research services (Syngene) revenue grew 2% YoY to INR26b, due to new order inflows, offset by weak demand in the earlier part of the year.
- Nonetheless, a step-up in new funding in the US biotech and shifting sourcing outside China may drive a recovery in demand for R&D services.
- The biologics facility acquired from Stelis Biopharma is expected to become operational in 2HFY25. Once operational, it will add 20 KL of biologics drug substance manufacturing capacity to Syngene's existing capabilities.
- Further, it has acquired 17 acres of land at Genome Valley for R&D services and expanding its offering in peptides, ADC and oligonucleotide.
- With a robust order book and a gradual pick-up in capacity utilization, we expect a 13% sales CAGR in SYNG research services to INR47b over FY25-27.

Reiterate Neutral


- While we maintain our sales/EBITDA estimates, we reduce our earnings estimates by 13%/4% for FY26/FY27, factoring in a higher tax rate. We value BIOS on SOTP basis (22x 12M forward EV/EBITDA for 73% stake in biocon biologics, 53% stake in Syngene and 14x EV/EBITDA for generics business) to arrive at a TP of INR420.
- With USFDA GMP compliance at Biocon park and Malaysia facility and b-Stellara approval, we expect the company's sales trajectory to strengthen going forward. In fact, the regulatory compliance provides better visibility for Insulin Aspart approval, which would be another niche opportunity for BIOS in FY26. We expect Syngene to also deliver better growth in FY25-27 compared to FY23-25 on the back of demand tailwinds and its capability/capacity. BIOS is implementing efforts in the peptide space within the generics segment, with commercial benefits expected FY26 onward. Maintain BUY.

Exhibit 9: P/E chart



Source: MOFSL, Company, Bloomberg


Exhibit 10: EV/EBITDA chart



Source: MOFSL, Company, Bloomberg


Story in charts

Exhibit 11: Expect revenue CAGR of ~15% over FY25–27




Source: MOFSL, Company

Exhibit 12: New launches/ramp-up to drive ex-Syngene revenue




Source: MOFSL, Company

Exhibit 13: R&D spending to expand 150bp as a % of sales over FY25–27




Source: MOFSL, Company

Exhibit 14: EBITDA margin to improve over FY25–27




Source: MOFSL, Company

Exhibit 15: RoE to improve gradually



Source: MOFSL, Company

Exhibit 16: Expect EPS to improve over FY25–27



Source: MOFSL, Company

Financials and valuations

Income Statement (Consolidated)										(INR m)
Y/E March	FY19	FY20	FY21	FY22	FY23	FY24	FY25E	FY26E	FY27E	
Net Income	55,144	63,005	71,058	81,845	1,10,774	1,44,051	1,48,077	1,67,162	1,95,343	
Change (%)	33.5	14.3	12.8	15.2	35.3	30.0	2.8	12.9	16.9	
Total Expenditure	41,211	46,974	54,504	61,922	85,810	1,14,580	1,18,643	1,31,621	1,51,375	
EBITDA	13,933	16,031	16,554	19,923	24,964	29,471	29,435	35,542	43,968	
Change (%)	68.0	15.1	3.3	20.4	25.3	18.1	-0.1	20.7	23.7	
Margin (%)	25.3	25.4	23.3	24.3	22.5	20.5	19.9	21.3	22.5	
Depreciation	4,478	5,522	7,145	8,150	11,131	15,690	16,700	17,682	18,214	
EBIT	9,455	10,509	9,409	11,773	13,833	13,781	12,734	17,860	25,754	
Int. & Finance Charges	709	649	577	686	4,183	9,750	8,911	7,632	7,155	
Other Income - Rec.	1,444	1,614	1,005	2,674	2,674	4,100	1,900	2,300	2,320	
Extraordinary income	1,946	675	910	-3,946	-1,042	7,940	10,990			
Share in Profits in JV					-1,666	-840	0	0	0	
PBT	12,136	12,149	10,747	9,815	9,616	15,231	16,714	12,528	20,918	
Tax	2,123	3,151	2,222	2,116	2,560	2,280	5,850	3,758	5,230	
Tax Rate (%)	17.5	25.9	20.7	21.6	26.6	15.0	35.0	30.0	25.0	
Minority Interest	964	1227	1051	1220	1810	2750	3438	4125	4950	
Adjusted PAT	7,441	7,410	6,077	8,825	7,491	2,164	-171	4,644	10,739	
PAT	9,053	7,769	7,438	6,479	5,246	10,201	7,426	4,644	10,739	
Change (%)	101.7	-0.4	-18.0	45.2	-15.1	-71.1	NA	NA	131.2	
Margin (%)	16.4	12.3	10.5	7.9	4.7	7.1	5.0	2.8	5.5	

Consolidated Balance Sheet										(INR m)
Y/E March	FY19	FY20	FY21	FY22	FY23	FY24	FY25E	FY26E	FY27E	
Equity Share Capital	3,000	6,000	6,000	6,003	6,000	6,000	6,000	6,000	6,000	
Revaluation Reserves	0	0	0	0	0	0	0	0	0	
Other Reserves	57,980	61,058	70,269	78,322	1,72,670	1,91,830	1,97,086	2,00,373	2,07,972	
Net Worth	60,980	67,058	76,269	84,325	1,78,670	1,97,830	2,03,086	2,06,373	2,13,972	
Loans	18,028	19,797	36,783	51,466	1,80,190	1,62,760	1,61,260	1,59,760	1,58,260	
Minority Interest	6,089	6,773	8,807	10,375	46,220	54,910	58,348	62,473	67,423	
Deferred liabilities	5816	13794	24212	25827	52440	17480	17480	17480	17480	
Capital Employed	90,913	1,07,422	1,46,071	1,71,993	4,57,520	4,32,980	4,40,173	4,46,085	4,57,134	
Gross Block	68,240	85,167	93,959	1,03,295	1,27,440	1,44,540	1,51,040	1,57,540	1,64,040	
Less: Accum. Deprn.	25,713	31,235	38,386	46,528	54,670	70,360	87,060	1,04,742	1,22,956	
Net Fixed Assets	42,527	53,932	55,573	56,767	72,770	74,180	63,980	52,798	41,084	
Capital WIP	12,869	15,765	22,535	34,203	25,880	39,850	39,850	39,850	39,850	
Investments	10,118	9,661	19,519	15,879	20,700	10,000	37,133	38,084	30,356	
Intangibles	8,303	11,974	13,533	15,824	2,69,200	2,72,850	2,72,850	2,83,764	3,12,140	
Curr. Assets	44,860	49,426	70,986	78,334	1,28,880	1,61,180	1,50,907	1,66,693	1,88,908	
Inventory	10,316	14,359	18,666	22,982	42,440	49,440	49,089	53,583	59,941	
Account Receivables	12,918	12,237	12,176	20,582	35,730	62,310	61,259	67,323	75,461	
Cash and Bank Balance	10,572	9,986	20,154	17,475	24,010	22,590	4,868	5,496	6,422	
Loans & Advances	11,054	12,844	19,990	17,295	26,700	26,840	35,691	40,291	47,084	
Curr. Liability & Prov.	27,764	33,336	36,075	29,014	59,910	1,25,080	1,24,547	1,35,104	1,55,204	
Account Payables	26,959	32,306	34,981	27,709	58,420	1,17,310	1,15,622	1,25,028	1,43,430	
Provisions	805	1,030	1,094	1,305	1,490	7,770	8,925	10,076	11,774	
Net Current Assets	17,096	16,090	34,911	49,320	68,970	36,100	26,360	31,590	33,704	
Appl. of Funds	90,913	1,07,422	1,46,071	1,71,993	4,57,520	4,32,980	4,40,173	4,46,085	4,57,134	

E: MOSL Estimates

Financials and valuations

Ratios

Y/E March	FY19	FY20	FY21	FY22	FY23	FY24	FY25E	FY26E	FY27E
Basic (INR)									
EPS	6.2	6.2	5.1	7.4	6.2	1.8	-0.1	3.9	9.0
Cash EPS	11.3	11.1	12.2	12.2	13.6	21.6	20.1	18.6	24.1
BV/Share	50.8	55.9	63.6	70.3	148.9	164.9	169.2	172.0	178.3
DPS	0.5	1.6	0.0	1.3	1.1	2.1	1.5	1.0	2.2
Payout (%)	7.8	29.3	0.0	29.3	29.3	29.3	29.3	29.3	29.3
Valuation (x)									
P/E	57.6	57.8	70.5	48.5	57.2	198.0	NA	92.2	39.9
Cash P/E	31.7	32.2	29.4	29.3	26.2	16.5	17.8	19.2	14.8
P/BV	7.0	6.4	5.6	5.1	2.4	2.2	2.1	2.1	2.0
EV/Sales	7.7	6.8	6.0	5.5	5.1	3.9	3.7	3.3	2.8
EV/EBITDA	30.6	26.7	25.7	22.4	22.6	19.0	18.6	15.3	12.5
Dividend Yield (%)	0.1	0.5	0.0	0.4	0.3	0.6	0.4	0.3	0.6
Return Ratios (%)									
RoE	16.1	12.1	8.5	11.0	5.7	1.1	-0.1	2.3	5.1
RoCE	10.7	9.1	6.5	7.1	3.8	3.4	2.2	3.2	4.7
RoIC	14.5	12.0	9.6	9.8	4.1	3.1	2.3	3.5	5.2
Working Capital Ratios									
Fixed Asset Turnover (x)	1.4	1.3	1.3	1.5	1.7	2.0	2.1	2.9	4.2
Debtor (Days)	86	71	63	92	118	158	151	147	141
Inventory (Days)	68	83	96	102	140	125	121	117	112
Creditors (Days)	178	187	180	124	192	297	285	273	268
Working Capital (Days)	43	35	76	142	148	34	53	57	51
Leverage Ratio (x)									
Current ratio	1.6	1.5	2.0	2.7	2.2	1.3	1.2	1.2	1.2
Net Debt/Equity	0.1	0.1	0.2	0.4	0.9	0.7	0.8	0.7	0.7

Consolidated Cash Flow Statement

(INR m)

Y/E March	FY19	FY20	FY21	FY22	FY23	FY24	FY25E	FY26E	FY27E
Oper. Profit/(Loss) before Tax	10,026	8,709	8,462	7,716	6,430	12,978	29,435	35,542	43,968
Interest/Dividends Recd.	-908	-824	-770	-1,121	-1,124	-1,613	1,900	2,300	2,320
Direct Taxes Paid	-2,915	-3,441	-1,938	-2,620	-2,286	-2,923	-5,850	-3,758	-5,230
(Inc)/Dec in WC	-291	-1,651	-4,238	-7,895	-5,010	-6,352	-7,982	-4,602	-1,188
CF from Operations	11,546	12,831	11,597	11,766	18,525	29,539	20,974	29,481	39,870
(Incr)/Dec in FA	-14,924	-18,436	-17,559	-19,269	17,242	-24,615	-6,500	-6,500	-6,500
Free Cash Flow	-3,378	-5,605	-5,962	-7,503	35,767	4,924	14,474	22,981	33,370
(Pur)/Sale of Investments	6,984	1,844	-18,512	2,314	-1,60,060	14,570	-27,133	-11,865	-20,649
CF from investments	-7,138	-15,589	-36,247	-16,991	-1,42,818	-10,045	-33,633	-18,365	-27,149
Change in Net Worth	-692	25	314	425	12,016	307	7,598	2	1
(Inc)/Dec in Debt	75	186	5,872	3,213	1,24,159	-13,130	-1,500	-1,500	-1,500
Interest Paid	-1,007	-912	-1,160	-1,096	-4,856	-8,474	-8,911	-7,632	-7,155
Dividend Paid	-793	-701	0	0	-718	-2,030	-2,172	-1,358	-3,141
CF from Fin. Activity	-2,417	3,988	26,176	2,154	1,31,527	-21,915	-5,884	-10,489	-11,794
Inc/Dec of Cash	1,991	1,230	1,526	-3,071	7,234	-2,421	-18,544	627	927
Add: Beginning Balance	4,490	6,481	7,711	9,237	6,166	13,400	10,979	-7,565	-6,937
Closing Balance	6,481	7,711	9,237	6,166	13,400	10,979	-7,565	-6,937	-6,010
FX	112	536	71	33	29	1,030	1,852	1,852	1,852
Bankc balances/Overdraft	3,979	1,739	10,846	11,276	10,581	10,581	10,581	10,581	10,581
Total Cash and cash Eq	10,572	9,986	20,154	17,475	24,010	22,590	4,868	5,496	6,423

E: MOSL Estimates

Investment in securities market are subject to market risks. Read all the related documents carefully before investing

NOTES

Explanation of Investment Rating	
Investment Rating	Expected return (over 12-month)
BUY	>=15%
SELL	< - 10%
NEUTRAL	< - 10 % to 15%
UNDER REVIEW	Rating may undergo a change
NOT RATED	We have forward looking estimates for the stock but we refrain from assigning recommendation

*In case the recommendation given by the Research Analyst is inconsistent with the investment rating legend for a continuous period of 30 days, the Research Analyst shall be within following 30 days take appropriate measures to make the recommendation consistent with the investment rating legend.

Disclosures

The following Disclosures are being made in compliance with the SEBI Research Analyst Regulations 2014 (herein after referred to as the Regulations).

Motilal Oswal Financial Services Ltd. (MOFSL) is a SEBI Registered Research Analyst having registration no. INH000000412. MOFSL, the Research Entity (RE) as defined in the Regulations, is engaged in the business of providing Stock broking services, Depository participant services & distribution of various financial products. MOFSL is a listed public company, the details in respect of which are available on www.motilaloswal.com. MOFSL (erstwhile Motilal Oswal Securities Limited - MOSL) is registered with the Securities & Exchange Board of India (SEBI) and is a registered Trading Member with National Stock Exchange of India Ltd. (NSE) and Bombay Stock Exchange Limited (BSE), Multi Commodity Exchange of India Limited (MCX) and National Commodity & Derivatives Exchange Limited (NCDEX) for its stock broking activities & is Depository participant with Central Depository Services Limited (CDSL) National Securities Depository Limited (NSDL), NERL, COMRIS and CCR and is member of Association of Mutual Funds of India (AMFI) for distribution of financial products and Insurance Regulatory & Development Authority of India (IRDA) as Corporate Agent for insurance products. Details of associate entities of Motilal Oswal Financial Services Limited are available on the website at <http://onlinereports.motilaloswal.com/Dormant/documents/List%20of%20Associate%20companies.pdf>. MOFSL and its associate company(ies), their directors and Research Analyst and their relatives may; (a) from time to time, have a long or short position in, act as principal in, and buy or sell the securities or derivatives thereof of companies mentioned herein. (b) be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the company(ies) discussed herein or act as an advisor or lender/borrower to such company(ies) or may have any other potential conflict of interests with respect to any recommendation and other related information and opinions.; however the same shall have no bearing whatsoever on the specific recommendations made by the analyst(s), as the recommendations made by the analyst(s) are completely independent of the views of the associates of MOFSL even though there might exist an inherent conflict of interest in some of the stocks mentioned in the research report.

MOFSL and / or its affiliates do and seek to do business including investment banking with companies covered in its research reports. As a result, the recipients of this report should be aware that MOFSL may have a potential conflict of interest that may affect the objectivity of this report. Compensation of Research Analysts is not based on any specific merchant banking, investment banking or brokerage service transactions. Details of pending Enquiry Proceedings of Motilal Oswal Financial Services Limited are available on the website at <https://galaxy.motilaloswal.com/ResearchAnalyst/PublishViewLitigation.aspx>

A graph of daily closing prices of securities is available at www.nseindia.com, www.bseindia.com. Research Analyst views on Subject Company may vary based on Fundamental research and Technical Research. Proprietary trading desk of MOFSL or its associates maintains arm's length distance with Research Team as all the activities are segregated from MOFSL research activity and therefore it can have an independent view with regards to Subject Company for which Research Team have expressed their views.

Regional Disclosures (outside India)

This report is not directed or intended for distribution to or use by any person or entity resident in a state, country or any jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject MOFSL & its group companies to registration or licensing requirements within such jurisdictions.

For Hong Kong:

This report is distributed in Hong Kong by Motilal Oswal capital Markets (Hong Kong) Private Limited, a licensed corporation (CE AYY-301) licensed and regulated by the Hong Kong Securities and Futures Commission (SFC) pursuant to the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) "SFO". As per SEBI (Research Analyst Regulations) 2014 Motilal Oswal Securities (SEBI Reg. No. INH000000412) has an agreement with Motilal Oswal capital Markets (Hong Kong) Private Limited for distribution of research report in Hong Kong. This report is intended for distribution only to "Professional Investors" as defined in Part I of Schedule 1 to SFO. Any investment or investment activity to which this document relates is only available to professional investor and will be engaged only with professional investors." Nothing here is an offer or solicitation of these securities, products and services in any jurisdiction where their offer or sale is not qualified or exempt from registration. The Indian Analyst(s) who compile this report is/are not located in Hong Kong & are not conducting Research Analysis in Hong Kong.

For U.S.

Motilal Oswal Financial Services Limited (MOFSL) is not a registered broker - dealer under the U.S. Securities Exchange Act of 1934, as amended (the "1934 act") and under applicable state laws in the United States. In addition MOFSL is not a registered investment adviser under the U.S. Investment Advisers Act of 1940, as amended (the "Advisers Act" and together with the 1934 Act, the "Acts"), and under applicable state laws in the United States. Accordingly, in the absence of specific exemption under the Acts, any brokerage and investment services provided by MOFSL, including the products and services described herein are not available to or intended for U.S. persons. This report is intended for distribution only to "Major Institutional Investors" as defined by Rule 15a-6(b)(4) of the Exchange Act and interpretations thereof by SEC (henceforth referred to as "major institutional investors"). This document must not be acted on or relied on by persons who are not major institutional investors. Any investment or investment activity to which this document relates is only available to major institutional investors and will be engaged in only with major institutional investors. In reliance on the exemption from registration provided by Rule 15a-6 of the U.S. Securities Exchange Act of 1934, as amended (the "Exchange Act") and interpretations thereof by the U.S. Securities and Exchange Commission ("SEC") in order to conduct business with Institutional Investors based in the U.S., MOFSL has entered into a chaperoning agreement with a U.S. registered broker-dealer, Motilal Oswal Securities International Private Limited. ("MOSIPL"). Any business interaction pursuant to this report will have to be executed within the provisions of this chaperoning agreement. The Research Analysts contributing to the report may not be registered /qualified as research analyst with FINRA. Such research analyst may not be associated persons of the U.S. registered broker-dealer, MOSIPL, and therefore, may not be subject to NASD rule 2711 and NYSE Rule 472 restrictions on communication with a subject company, public appearances and trading securities held by a research analyst account.

For Singapore

In Singapore, this report is being distributed by Motilal Oswal Capital Markets (Singapore) Pte. Ltd. ("MOCMSPL") (UEN 201129401Z), which is a holder of a capital markets services license and an exempt financial adviser in Singapore. This report is distributed solely to persons who (a) qualify as "institutional investors" as defined in section 4A(1)(c) of the Securities and Futures Act of Singapore ("SFA") or (b) are considered "accredited investors" as defined in section 2(1) of the Financial Advisers Regulations of Singapore read with section 4A(1)(a) of the SFA. Accordingly, if a recipient is neither an "institutional investor" nor an "accredited investor", they must immediately discontinue any use of this Report and inform MOCMSPL.

In respect of any matter arising from or in connection with the research you could contact the following representatives of MOCMSPL. In case of grievances for any of the services rendered by MOCMSPL write to grievances@motilaloswal.com.

Nainesh Rajani

Email: nainesh.rajani@motilaloswal.com

Contact: (+65) 8328 0276

Specific Disclosures

- 1 MOFSL, Research Analyst and/or his relatives does not have financial interest in the subject company, as they do not have equity holdings in the subject company.
- 2 MOFSL, Research Analyst and/or his relatives do not have actual/beneficial ownership of 1% or more securities in the subject company
- 3 MOFSL, Research Analyst and/or his relatives have not received compensation/other benefits from the subject company in the past 12 months
- 4 MOFSL, Research Analyst and/or his relatives do not have material conflict of interest in the subject company at the time of publication of research report
- 5 Research Analyst has not served as director/officer/employee in the subject company
- 6 MOFSL has not acted as a manager or co-manager of public offering of securities of the subject company in past 12 months
- 7 MOFSL has not received compensation for investment banking/ merchant banking/brokerage services from the subject company in the past 12 months
- 8 MOFSL has not received compensation for other than investment banking/merchant banking/brokerage services from the subject company in the past 12 months
- 9 MOFSL has not received any compensation or other benefits from third party in connection with the research report
- 10 MOFSL has not engaged in market making activity for the subject company

The associates of MOFSL may have:

- financial interest in the subject company
- actual/beneficial ownership of 1% or more securities in the subject company at the end of the month immediately preceding the date of publication of the Research Report or date of the public appearance.
- received compensation/other benefits from the subject company in the past 12 months
- any other potential conflict of interests with respect to any recommendation and other related information and opinions.; however the same shall have no bearing whatsoever on the specific recommendations made by the analyst(s), as the recommendations made by the analyst(s) are completely independent of the views of the associates of MOFSL even though there might exist an inherent conflict of interest in some of the stocks mentioned in the research report.
- acted as a manager or co-manager of public offering of securities of the subject company in past 12 months
- be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the company(ies) discussed herein or act as an advisor or lender/borrower to such company(ies)

- received compensation from the subject company in the past 12 months for investment banking / merchant banking / brokerage services or from other than said services.
- Served subject company as its clients during twelve months preceding the date of distribution of the research report.
- The associates of MOFSL has not received any compensation or other benefits from third party in connection with the research report.
- Above disclosures include beneficial holdings lying in demat account of MOFSL which are opened for proprietary investments only. While calculating beneficial holdings, It does not consider demat accounts which are opened in name of MOFSL for other purposes (i.e holding client securities, collaterals, error trades etc.). MOFSL also earns DP income from clients which are not considered in above disclosures.

Analyst Certification

The views expressed in this research report accurately reflect the personal views of the analyst(s) about the subject securities or issues, and no part of the compensation of the research analyst(s) was, is, or will be directly or indirectly related to the specific recommendations and views expressed by research analyst(s) in this report.

Terms & Conditions:

This report has been prepared by MOFSL and is meant for sole use by the recipient and not for circulation. The report and information contained herein is strictly confidential and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of MOFSL. The report is based on the facts, figures and information that are considered true, correct, reliable and accurate. The intent of this report is not recommendatory in nature. The information is obtained from publicly available media or other sources believed to be reliable. Such information has not been independently verified and no guaranty, representation of warranty, express or implied, is made as to its accuracy, completeness or correctness. All such information and opinions are subject to change without notice. The report is prepared solely for informational purpose and does not constitute an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments for the clients. Though disseminated to all the customers simultaneously, not all customers may receive this report at the same time. MOFSL will not treat recipients as customers by virtue of their receiving this report.

Disclaimer:

The report and information contained herein is strictly confidential and meant solely for the selected recipient and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent. This report and information herein is solely for informational purpose and may not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Nothing in this report constitutes investment, legal, accounting and tax advice or a representation that any investment or strategy is suitable or appropriate to your specific circumstances. The securities discussed and opinions expressed in this report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient. This may not be taken in substitution for the exercise of independent judgment by any recipient. Each recipient of this document should make such investigations as it deems necessary to arrive at an independent evaluation of an investment in the securities of companies referred to in this document (including the merits and risks involved), and should consult its own advisors to determine the merits and risks of such an investment. The investment discussed or views expressed may not be suitable for all investors. Certain transactions -including those involving futures, options, another derivative products as well as non-investment grade securities - involve substantial risk and are not suitable for all investors. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information and opinions contained in this document. The Disclosures of Interest Statement incorporated in this document is provided solely to enhance the transparency and should not be treated as endorsement of the views expressed in the report. This information is subject to change without any prior notice. The Company reserves the right to make modifications and alterations to this statement as may be required from time to time without any prior approval. MOFSL, its associates, their directors and the employees may from time to time, effect or have effected an own account transaction in, or deal as principal or agent in or for the securities mentioned in this document. They may perform or seek to perform investment banking or other services for, or solicit investment banking or other business from, any company referred to in this report. Each of these entities functions as a separate, distinct and independent of each other. The recipient should take this into account before interpreting the document. This report has been prepared on the basis of information that is already available in publicly accessible media or developed through analysis of MOFSL. The views expressed are those of the analyst, and the Company may or may not subscribe to all the views expressed therein. This document is being supplied to you solely for your information and may not be reproduced, redistributed or passed on, directly or indirectly, to any other person or published, copied, in whole or in part, for any purpose. This report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject MOFSL to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to certain category of investors. Persons in whose possession this document may come are required to inform themselves of and to observe such restriction. Neither the Firm, not its directors, employees, agents or representatives shall be liable for any damages whether direct or indirect, incidental, special or consequential including lost revenue or lost profits that may arise from or in connection with the use of the information. The person accessing this information specifically agrees to exempt MOFSL or any of its affiliates or employees from, any and all responsibility/liability arising from such misuse and agrees not to hold MOFSL or any of its affiliates or employees responsible for any such misuse and further agrees to hold MOFSL or any of its affiliates or employees free and harmless from all losses, costs, damages, expenses that may be suffered by the person accessing this information due to any errors and delays.

This report is meant for the clients of Motilal Oswal only.

Investment in securities market are subject to market risks. Read all the related documents carefully before investing.

Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

Registered Office Address: Motilal Oswal Tower, Rahimtullah Sayani Road, Opposite Parel ST Depot, Prabhadevi, Mumbai-400025; Tel No.: 022 - 71934200 / 71934263; www.motilaloswal.com.

Correspondence Address: Palm Spring Centre, 2nd Floor, Palm Court Complex, New Link Road, Malad (West), Mumbai- 400 064. Tel No: 022 71881000. Details of Compliance Officer: Neeraj Agarwal, Email Id: na@motilaloswal.com, Contact No.:022-40548085.

Grievance Redressal Cell:

Contact Person	Contact No.	Email ID
Ms. Hemangi Date	022 40548000 / 022 67490600	query@motilaloswal.com
Ms. Kumud Upadhyay	022 40548082	servicehead@motilaloswal.com
Mr. Ajay Menon	022 40548083	am@motilaloswal.com

Registration details of group entities.: Motilal Oswal Financial Services Ltd. (MOFSL): INZ000158836 (BSE/NSE/MCX/NCDEX); CDSL and NSDL: IN-DP-16-2015; Research Analyst: INH000000412 . AMFI: ARN : 146822. IRDA Corporate Agent – CA0579. Motilal Oswal Financial Services Ltd. is a distributor of Mutual Funds, PMS, Fixed Deposit, Insurance, Bond, NCDs and IPO products.

Customer having any query/feedback/ clarification may write to query@motilaloswal.com. In case of grievances for any of the services rendered by Motilal Oswal Financial Services Limited (MOFSL) write to grievances@motilaloswal.com, for DP to dpgrievances@motilaloswal.com.